Work

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Year: 2010

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-010-1377-y

Authors: E. Claire Dees, Jeffrey R. Infante, Roger B. Cohen, Bert H. O’Neil, Suzanne Jones, Margaret von Mehren, Hadi Danaee, Yih Lee, Jeffrey Ecsedy, Mark Manfredi, Katherine Galvin, Bradley Stringer, Hua Liu, Omar Eton, Howard Fingert, Howard Burris

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Sarah Cannon Research Institute, Sarah Cannon, Fox Chase Cancer Center, Takeda Oncology (United States), Forest Laboratories (United States), Boston University

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Takeda Oncology, National Cancer Institute, National Center for Research Resources

Awards: G156276794, G206438753, G251702431, G3228124329, G488872913

OpenAlex ID: W2007608739

FWCI: 3.924

Cites: 32

Cited by: 76

Related to: 10